Department of Orthopedic, The Second Affiliated Hospital of Jiaxing University, Jiaxing, China.
Department of Radiotherapy, 74567Affiliated Hospital of Nantong University, Nantong, China.
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820947701. doi: 10.1177/1533033820947701.
Osteosarcoma is a rare type of bone tumor, and this study aimed to assess the clinicopathologic features and prognoses of osteosarcoma patients.
Clinicopathologic and survival data of 1025 patients between 2010 and 2016, 230 between 2008 and 2009 were downloaded and analyzed from the SEER database. Patients' survival was analyzed using the Kaplan-Meier analysis; prognostic factors were assessed using the Cox regression hazards model. The 1-, 3-, and 5-year survival rates were estimated with nomogram. Competitive risk models were used to identify prognostic risk factors related to endpoint events of osteosarcoma patients.
Overall, 722 samples were obtained from the extremities, 134 from the axial bones, and 119 from the cranial and mandible in SEER (2010-2016 cohort). After the preliminary diagnosis, the median survival time of patients with osteosarcoma was 39 months, and the 1-, 3-, and 5-year survival rates were 87.3%, 67.2%, and 58.0%, respectively (P < 0.001). The competitive risk model revealed no competitive risks of the endpoint event.
Our study found out the prognostic factors in patients with Osteosarcoma by Cox regression hazards model, after that, nomogram was established to predict the 1-, 3-, and 5-year survival rates, which may help oncologists to understand the highly malignant tumor.
骨肉瘤是一种罕见的骨肿瘤，本研究旨在评估骨肉瘤患者的临床病理特征和预后。
从 SEER 数据库中下载并分析了 2010 年至 2016 年期间的 1025 例患者和 2008 年至 2009 年期间的 230 例患者的临床病理和生存数据。使用 Kaplan-Meier 分析评估患者的生存情况；使用 Cox 回归风险模型评估预后因素。使用列线图估计 1、3 和 5 年的生存率。竞争风险模型用于确定与骨肉瘤患者终点事件相关的预后危险因素。
总体而言，SEER（2010-2016 队列）中 722 例样本来自四肢，134 例来自轴骨，119 例来自颅面和下颌骨。初步诊断后，骨肉瘤患者的中位生存时间为 39 个月，1、3 和 5 年的生存率分别为 87.3%、67.2%和 58.0%（P<0.001）。竞争风险模型显示终点事件无竞争风险。
我们的研究通过 Cox 回归风险模型发现了骨肉瘤患者的预后因素，然后建立了列线图来预测 1、3 和 5 年的生存率，这可能有助于肿瘤学家了解高度恶性肿瘤。
